Oral Diagnostics; Clinical Oral Oncology; Premalignancy; Mucocutaneous Diseases; Xerostomia; Laser Dentistry and Environmentally Friendly
Dr. Ben F. Warner is Clinical Associate Professor at the University of Texas School of Dentistry in the Department of General Practice and Dental Public Health, where he serves as First Attending. He is a member of the Advisory Committee for the Dental Assisting Program, Coleman College for Health Sciences in the Texas Medical Center, Houston Community College. He serves on numerous boards, committees and charitable organizations, as well as, presents educational talks to doctors, students and the public.
He graduated from the University of St. Thomas - Houston with a B.A. in Biology. He completed a Neurophysiology research program with a M.S. from the University of Houston and attended the University of Texas School of Dentistry - Houston receiving a D.D.S. in 1979. After practicing for a decade, he returned to the world renowned Texas Medical Center and obtained a M.D. at the University of Texas Medical School - Houston. There, he continued his training in combined residencies in Anatomic Pathology and Clinical Laboratory Medicine and served as Chief Resident. He was awarded an Oral Maxillofacial Head and Neck Fellowship from M. D. Anderson Cancer Center in the Department of Pathology. Additionally, his studies have included complementary and alternative medicine (CAM) such as Applied Kinesiology, Acupuncture, Magnet Therapy, Herbal Remedies, and Homeopathic Medicine.
Steven P Brownstein graduated from University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA in 1971-1975 and post graduate medical training residency in Diagnostic Radiology from Newark Beth Israel Medical center, Newark, New Jersey, USA. He acquired Board certification from American Board of Radiology in June 1981. And he got Professional experience as Medical Director since 1991 to present.
Cancer; Mitochondria; Diabetes; Orthomolecular Medicine and Intravenous Vitamin C
Michael J. Gonzalez is Professor at the Nutrition Program, School of Public Health in the Medical Sciences Campus, University of Puerto Rico and Adjunct faculty at the University of Western States. He earned a Bachelor Degree in Biology and Chemistry (Catholic University), a Masters in Cellular Biology and Biophysics (Nova University), and another Masters in Nutrition and Public Health (University of PR Med Sciences Campus). He has a Doctorate in Nutritional Medicine (John F. Kennedy University). He also has a Doctorate in Health Sciences (Lafayette University), and another Doctorate in Nutritional Biochemistry and Cancer Biology (Michigan State University). He completed a Post-Doctoral Fellowship in Geriatrics at the School of Medicine, University of Puerto Rico. Dr. Gonzalez is a Fellow of the American College of Nutrition, and has authored over 150 scientific publications. He has serve as a member on more than 15 scientific journal Editorial Boards, such as Biomedicina, the Journal of Orthomolecular Medicine, and Alternative Medicine Reviews. He has served as consultant for several companies, he has been responsible for designing formulations of nutritional supplements and pharmaceutical products. He has also been a consultant for The Center for the Improvement of Human Functioning (now Riordan Clinic), in Wichita, Kansas. He has obtained several research awards for his work on Nutrition and Cancer. He is currently Co- Director of RECNAC II project, and Research Director of the InBioMed Project Initiative. Dr. Gonzalez also serves as a nutrition consultant to the Puerto Rican Basketball National Team and is part of the Medical Commission of the Puerto Rican Basketball Federation. He is in a part time clinical practice with Dr. Miguel J Berdiel in Ponce, PR. In December 2013,Dr. Gonzalez was exalted as Distinguished Ponceńo in Medicine. In November 2014 he was selected as a member as the Academy of Arts and Sciences of Puerto Rico and to the Iberoamerican Academy of Sciences and Culture.
Doctor González and Dr. Jorge Miranda-Massari, founders of InBioMed, are leaders in the development of non-toxic chemotherapy treatments for cancer. The findings of their work with Intravenous Vitamin C as an anti-cancer agent, published in 2002, were confirmed by the NIH in 2005. They published the first Phase-I clinical study utilizing Intravenous Vitamin C for treatment of terminal cancer patients in 2005, and also published in 2005 the most comprehensive review on Vitamin C and Cancer, as a follow-up on the work of two times Nobel Laureate, Dr. Linus C. Pauling. They have brought many new concepts into the scientific field, such as the Bioenergetic theory of carcinogenesis, the systemic saturation phenomenon of intravenous vitamin C, the metabolic correction concept for disease treatment and prevention
Books: Doctors Gonzalez, Miranda-Massari and Sauls book I Have Cancer What Should I do: The Orthomolecular Guide to Cancer Management provides evidence based recommendations for an integrative approach for those dealing with cancer and seeking to improve quality of life and survival.
The book New Insights on Vitamin C and Cancer presents the current evidence on the use of Vitamin C in Cancer therapy.
Obstetrics & Gynecology; Gynecological Oncology
Georgios Androutsopoulos completed his Degree in Medicine in 1995, at the National and Kapodestrian University of Athens. He received his Medical Specialization in 2006, at the Department of Obstetrics - Gynecology of the University of Patras. He also completed his Doctorate of Medicine âPregnancy complications in Greek women with inherited thrombophiliaâ in 2007, at the same Department.
He started his clinical career in 1-8-2006, as Obstetrician - Gynecologist at the General, Maternity & Pediatric Hospital of Athens âMiteraâ and he served up until 20-1-2009. In 23-1-2009 he became a Consultant of Obstetrics and Gynecology at the General Hospital of Amfissas and he served up until 3-1-2012.
He started his academic career in 3-1-2012, as a Lecturer and Consultant of Obstetrics and Gynecology at the University of Patras and he served up until 20-10-2014. In 20-10-2014, he became an Assistant Professor and Consultant of Obstetrics and Gynecology at the University of Patras and he holds the same position until today.
He has got both academic and clinical experience as well as a heavy workload of research and educational duties. Moreover, he has actively participated in teaching the Medical Students of the University of Patras and in training program for the Specialty Trainees of the Department of Obstetrics and Gynecology. His research interests are mainly focused in Gynacological Oncology with 69 Publications in International Scientific Journals with Reviewers and 4 Chapters in Medical Books.
Central Military Hospital of El Salvador. Staff Surgeon. Period: August 1989 - March 2007. Phone: 2250-0080. Functions and achievements: Surgery and Oncology.
ARMECASAN Clinics. Medical Director. Period: March 1997 - May 2006. Phone: 2298-0499. Functions and achievements: Medical Director of Ambulatory Surgery Center.
Lamatepec ISSS hospital. Surgeon. Period: January 2005 - May 2006. Phone: 2297-9700. Functions and achievements: Surgeon. Emergency Unit.
âMedico Quirurgicoâ Hospital. Surgeon. Period: January 2002 - November 2004. Phone: 2261-9500. Functions and achievements: Surgeon. Emergency Unit.
Fertility Preservation of Female Patients with Cancer; Reproductive Medicine; Infertility; Assisted Reproductive Techniques (ART); Cross Border Reproductive Care (CBRC)
Mahmoud Abdelhalim Salama is an Assistant Professor and Consultant of Gynecology & Obstetrics. Currently, he conducts his Professorship Program at Medical Faculty - Cologne University - Germany. In 2012, He earned his PhD in Reproductive Medicine from Medical University of Innsbruck - Austria. Earlier, he earned his MBBCh of Human Medicine, MSc and MD of Gynecology & Obstetrics from Medical Faculty - Cairo University - Egypt. Recently in 2014, He earned a Master of Arts in Business (MA) in International Healthcare Management from Management Center Innsbruck - Austria.
Breast Cancer Surgeon; International Healthcare Leader; Advocate for the prevention of Breast Cancer; Social Entrepreneur
Kathleen Ruddy has Internationally acclaimed as a global healthcare leader for the âPure Cureâ - breast cancer prevention - Ruddy works tirelessly to promote primary prevention of breast cancer. She is especially committed to supporting research on the human breast cancer virus and the development of preventive breast cancer vaccines. Ruddyâs mission: To understand the specific causes of breast cancer and to use that knowledge to prevent the disease. Her vision: Persuade the world that Prevention Is The New Cure.
Ruddy has twice been recognized by the largest private insurer in New Jersey (Horizon Blue Cross Blue Shield of New Jersey) as an outstanding surgeon whose outcomes and cost-effectiveness are exemplary. Ruddy has twice received awards for her blog on the breasthealthandhealing.org website.
In 2008, Ruddy create the first breast cancer philanthropy dedicated to the primary prevention of breast cancer, the Breast Health & Healing Foundation (501c3). Ruddy became aware of the existence of a human breast cancer virus in 2007 and has dedicated the energies and resources of the Breast Health & Healing Foundation to increasing funding for this critically important research. As Ruddy says, âIf a virus causes breast cancer in women, we need to know about it now not in another 100 years.â At this point, scientists are converging on agreement: The human breast cancer virus appears to be involved in 40-94% of human breast cancer. It is found and passed in human saliva.
In her quest to raise awareness about the human breast cancer virus and its global implications for the Pure Cure, Ruddy spent eight years researching and writing, OF MICE AND WOMEN: Unraveling the Mystery of the Breast Cancer Virus, now available on Amazon. 100% of the proceeds from the sale of the book will be used to support research on the breast cancer virus.
Ruddy is an esteemed member of the Leadership Council of the Harvard School of Public Health.
Adaptive Radiation therapy of Head and Neck Cancer Gender differences in autoimmune diseases (Lupus and Diabetes). Bisphenol A (Estrogen) in activation of type IIFN-signaling: implications for the development of autoimmune diseases. Inflammasome activation and development of atherosclerosis and arthritis diseases. Hypoxia activates inflammasomes and cancers and associated disease.
Ravichandran Panchanathan Research Health Scientist -Feb2007-till date Cincinnati VA Medical Center, Cincinnati, OH Senior Scientist- 2016 âDept of Radiation Oncology University of Cincinnati Scientist- 2008 -2015. Dept of Environmental Health University of Cincinnati. Research Associate -2007 to -2008 November, Dept of Environmental Health University of Cincinnati. Research Scientist 2006-Jan-2007 Hines VA Medical Center, Chicago,IL. Research Associate -2006 to feb-2007 Jan, Dept of Radition Oncology, Loyola University, Chicago, IL. Postdoctoral Associate -2004 to feb-2006, Depart of Pathology, Emory University, Atlanta GA. Postdoctoral Fellow- Jan-2004 to june-2004, Dept of Anatomy, Chang Gung University Taiwan. Postdoctoral Fellow- June-1999 to 2004, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan. Research Associate -from 1998 March to May -1999.Department of Biochemistry and Molecular Biology, University of Madras
National Cancer Institute Rosa Tavares (INCART) Dominican Republic View Profile
Advanced Techniques in Radiation Therapy; Radiation Oncology and Nuclear Medicine
Chief of Radiation Oncology Department at National Cancer Institute Rosa Tavares (INCART) in Santo Domingo, Chief of Stereotactic Radiosurgery Unit at Cancer Center Metropolitan Hospital of Santiago, in El Cibao, External Advisory at CDD Radiotherapy â Clinica Abreu in Santo Domingo, Assistant Professor and Consultant in the only one residency program of Radiation Oncology in Dominican Republic, at CDD Radiotherapy in Clinica Abreu.
American University of Beirut Medical Center Lebanon View Profile
External Beam Radiotherapy; Brachytherapy; Modeling and Simulation: Monte Carlo Methods (EGS/BEAMnrc & MCNP) in radiotherapy; Programing: MATLAB (in radiotherapy)
Alexander Osman is currently Medical Physicist Resident at Department of Radiation Oncology at American University of Beirut Medical Center (AUBMC), Lebanon. Prior to this he was doing research at King Fahd University of Petroleum and Minerals (KFUPM) in Saudi Arabia, where he earned his MS degree in Medical Physics (2015). He had a BSc degree in Medical Physics from Al-Neelain University in Sudan (2008). He attended and participated in several regional and global conferences. His research works in Medical Physics - Radiation Therapy Physics are now under progress for publication in peer review journals. He is also a member of the American Association of Physicist in Medicine (AAPM) the Institute of Electrical and Electronics Engineering (IEEE) society (2015 to present).
Optimizing MRI for Radiation Treatment Planning; MRI QA/QC procedure for MR guided Radiation Treatment Planning (MRgRTP); MR guided Brain Stereotactic radiosurgery (SRS); MR based Radiation Treatment Planning (MRgRTP); Imaging-Based Assessments of Tumor Response; Quantitative MRI as a metric for adaptive radiation therapy and tumor post respond measuremet
Dr. Ali Fatemi-Ardekani done his Ph. D in McMaster University, Canada,under the guidance of Dr. Michael Noseworthy and Dr.Mark Haacke two world-renowned MRI physicists. His work focused on
coding and optimization of a new high-resolution quantitative MRI pulse sequence called
Susceptibility Weighted Imaging (SWI). This sequence has wide verities of clinical applications
and research in different fields of medicine. That can be included; Quantitative detection of
Traumatic brain injury (TBI), Stroke and hemorrhage, Sturge-Weber disease, Tumours, Multiple
sclerosis, Vascular dementia, cerebral amyloid angiopathy (CAA) and Pneumocephalus.
Institut des Technologies AvancĂŠes en sciences du Vivant (ITAV) France View Profile
Cancer cell biology; Cell cycle control; 3D models; Microscopy
Bernard Ducommun graduated from the University of Toulouse, France in 1984 (MD) and 1988 (PhD). He was a post doctoral fellow at Cold Spring Harbor laboratories (NY, USA) and at the European Molecular Biology Laboratory (Heidelberg, Germany). He is professor of cancer biology at the medical school of the University of Toulouse and is the director of the Institute for Advanced Technology in Life sciences. His research interest focuses on tumoral cell dynamics and proliferation in 3D models, giving much attention to the systemic study of the biology of cell cycle control and cell fate.
Dr. Saurabh G. Vispute is a Research Scientist in the Toxicology department at Charles River Laboratories, Reno, NV. At Charles River, he serves as a Study Director and is responsible for design, conduct, interpretation, and reports of GLP and non-GLP preclinical toxicity studies of potential drug candidates in rodents and non-human primates. Dr. Vispute earned his PhD in Pharmacology from St. Johnâs University, New York in December 2015. His graduate research focused on characterizing the regulation of Fibroblast growth factor (Fgf) 21 and its pharmacological/toxicological implications. Dr. Vispute has a Bachelorâs degree in Pharmacy from Mumbai University, India (2009) and is a registered Pharmacist in India. He has several publications in peer reviewed journals and has given presentations at international scientific meetings. Dr. Visputeâs academic achievement has been recognized by scientific organizations such as Society of Toxicology (SOT), American Association of Pharmaceutical Scientists (AAPS), and American Society for Pharmacology and Experimental Therapeutics (ASPET) by awarding him several graduate student awards and scholarships. In addition, Dr. Vispute volunteers as a reviewer for peer-reviewed journals and is actively involved in various groups/sections and programs within SOT and ASPET such as MASOT, ASIO, ASPET Mentoring Network, etc. He is currently serving as a Chair of ASIO Newsletter Committee. Dr. Vispute continues to explore opportunities to contribute to the society and give back to the scientific community as well as mentor upcoming graduate students.
Hematology and Oncology; Molecular Testing
CSO, VP, General Manager, Scientific Director, Project Leader, Principal Investigator, 5P Dx, IVD Molecular Diagnostics/Advanced Technology/Clinical Test/Drug Discovery/Assay Development /Stem Cell Biology/Signal Transduction/Apoptosis, 20-year experience of Mol Dx/CLIA/CAP/FDA/biotech/pharmaceutical/clinical research and project management, and of successfully leading projects to proof of concept in animals. Excellent skills in supervising people, and an extensive track record of outstanding productivity
Consultant Clinical Pharmacist &Head of Clinical Pharmacy Al Shorouk Hospital, Cairo, Egypt 1st of June 2010 to 31st of May 2012
Consultant Oncology/haematology Clinical Pharmacist
â˘Head of Clinical Pharmacy Department
â˘Co-Chairman of Pharmacy and therapeutic Committee.
Oncology Pharmacist Deputation from National Cancer Institute, Cairo University to King Faisal specialist Hospital and Research Centre, Riyadh (JCIA Affiliated Tertiary Care Health Facility)
12th of Dec. 2006 to 19th of Sep. 2009
Applying my Oncology And Haematology Clinical experiences as Oncology outpatient Pharmacist reviewing medication, drug interaction, proper use of medication, advise other health care professionals on drug usage, dispensing and counselling Cancer patients on taking home Chemo and non-Chemo medications and on related issues according to the treatment protocols .
All haematology and oncology patients required high professional Cancer drug counselling, drug interactions, and monitoring of their adverse effects. I am responsible for this activity to ensure patient safety and counselling by applying my Oncology Clinical Pharmacy experiences.
Sep 1999 â Nov 2006
ď§From September 1999 to December 2001:
Paediatric Haematology & Oncology Clinical Pharmacist.
ď§From December 2001 to December 2003:
Adult Haematology & Oncology Clinical Pharmacist.
ď§From December 2003 to December 2006:
Head of Clinical Pharmacy Inpatient âMedical Oncology and Hematology" Unit.
- Supervise, put policies and advise on the following items:
oSharing in continuous education courses for Health Care Providers âas lecturerâ
oTranslation and interpretation of prescription orders.
oPatient drug profile review for allergies and drug interactions.
oAseptic Preparation of Cytotoxic, Antibiotics, Supportive drug Intravenous doses
oAppropriate nature of prescription orders in terms of drug, dosage, and directed use
oResolution of any prescription related issues with patients and/or physicians
oFinal review of prescription products prior to dispensing for accuracy of product and labeling.
oProviding information to and being available for counseling patients on effective use of prescriptionproducts and drug therapy management when appropriate.
oPatient counselling. - Sharing in planning and designing new Clinical Pharmacy units.
- Actively participating in clinical trials in association with international organization.
- Participating staff rounds and case studies and clinical consulting.
All types of Cancers; Cellular immunity in pancreatic cancers
Alfredo Addeo has graduated in 2001 at the school of medicine of Turin (Italy) and then had his residency at Sa Giovanni Battistaâs Hospital in Turin. He completed his specialist training in December 2005 and gained an MD research on dendritic cells and pancreatic extracellular environment. After working in Italy as consultant he moved to UK and joined the University Hospital Bristol trust where at the moment he manly treat lung cancer and melanoma patients. He is also actively collaborating with the university of Bristol where he is a research fellow. At the moment he is setting up a research project on ctDNA in lung cancer patients.
Growth factors and Antitumoral Immunity and cellular therapies of tumours
Adama Ly is the President - Founder of AFROCANCER, an international network against cancer in Africa. He is also the Founder in 2009 and editor in chief of the revue âJournal Africain du Cancer/ African Journal of Cancerâ published by Springer France.
Born in Senegal, Adama Ly is Doctor in Immunology and Oncology at University Paris XI and was member of the Doctoral school of Gustave Roussy cancer Institute (Villejuif, France). He received a degree in Biomedical Engineering and Innovations Management (Pierre and Marie Curie University, Paris, France). He graduated in Master of Social Health (MSH) from Ecoles des Hautes Etudes en Sciences Sociales (School of High studies in social Sciences) (Paris). He was visiting fellow at Sydney Kimmel Cancer Center (SKCC, San Diego, California, USA) and at Martin Luther Wittenberg University (Halle, Germany).
As senor manager in medical and fundamental researches, he focuses his work in growth factors and antitumoral immunity and cellular therapies of tumours at INSERM (National Institute for Health and Medical Research) and University Paris XI.
As a promoter of the fight against cancer in Africa, we were the co-editor of the book âAbout cancer in Africa, from Epidemiology to biomedical applications and perspectivesâ a multidisciplinary book with 136 authors from 32 countries worldwide, published by the French National cancer Institute. Preface of Pr. Jean Dausset, medicine Nobel Prize owner.
As Lead coordinator in Health and development, he is conducting a project aiming to build a Center for Cancer Prevention and research in Senegal to help reducing the impact of cancer in African populations and to boost knowledge and exchanges between develop and developing countries.
He has received international awards (Laureate of the 2011 Editorial Award attributed by the Syndicate of Health professionâs publishers and medias (Paris 20 October 2011), was elected ÂŤ Men of Year 2007 Âť with 14 other laureates by African medias and congratulations and Honours of International Atomic Energy Agency (IAEA), Vienna, Austria ( 20 September 2007)
Member of many professional societies and scientific boards, he has published several articles and books in cancer research and development.
Neuroradiology & Head and Neck; Musculoskeletal Imaging; Diagnostic Radiology; MRI-guided Navigation & Interventions
Associate Professor:2015âPresent,Division of MRI, Shandong Medical Imaging Research Institute, Shandong University, Jinan, China
Attending & AssistantRadiologist:2008â2015,Division of MRI and Interventional MRI, Shandong Medical Imaging Research Institute, Shandong University, Jinan, China
Residency: 2004â2008,Radiology,Shandong Medical Imaging Research Institute, Shandong University, Jinan, China
Internship, 2002 â2004, Radiology,Shandong Medical Imaging Research Institute, Shandong University, Jinan, China
gastrointestinal cancers , Hepatocellular cancers, Lung cancer , Hematological malignancies, ITP, leukaemia , Leukaemia, Oncology, Hematology, Radiotherapy , Transfusion medicine
Dr Piyush Vyas is a board certified clinical Oncologist , presently undergoing his next training in Clinical haematology. Dr Piyush Vyas has published many articles in peer reviewed journals, is /was member of many professional societies like ESMO, ASCO , AACR, Polish Society of Clinical Oncology.Dr Piyush Vyas is a clinician and also an academician teach undergraduate and postgraduate students at Medical University of Warsaw, Poland. Having had passed the ESMO(European Society of Medical Oncology) exam has shown his expertise on Oncological and haematological malignancies.His main interest is in haematological and oncological malignancies. His group was the first to administer chemotherapy in a patient with metastatic duodenal cancer with co-existent immune thrombocytopenic Purpura.
Leukemia (Acute and Chronic); Stem cell Transplant; Multiple myeloma; Lymphomas (Hodgkin and Non-Hodgkin); Coagulation and bleeding disorders; Quality Improvement
08/2000 â 12/2005 M.B.B.S, Dayanand Medical College and Hospital, Ludhiana, India
01/2008 â 12/2010 Internal Medicine Residency, Medical College of Wisconsin and Affiliated Hospitals, Milwaukee, WI
07/2011 â 06/2014 Hematology-ÂâOncology Fellowship, Medical College of Wisconsin and Affiliated Hospitals, Milwaukee, WI
07/2014 â 06/2015 Leukemia Fellowship, MD Anderson Cancer Center, Houston, TX
Oral Anatomy and Histology; Head &Neck Anatomy; Oncology
Nur Mohammad Monsur Hassan had been appointed in the School of Dentistry and Health Sciences, Charles Sturt University in 2013 as a teaching and research academic. He is a member of Royal Australasian College of Dental Surgeons.
He graduated with a Bachelor of Dental Science (BDS) in 2000 and completed his PhD from Geriatric dentistry, Graduate School of Dental Medicine, Hokkaido University, Japan in 2007. Then he achieved a postdoctoral award from the âCenter for Excellenceâ Japan and worked from 2007-2008 in the Cancer Related Gene, Institute of Genetic Medicine, Hokkaido Japan. After that, he achieved prestigious postdoctoral award from the âJapan Society for Promotion of Sciencesâ and worked in the Department of Oral and Maxillofacial Surgery and Biopathology, Okayama University, Japan from 2008-2010. Then he worked as a post-doctoral research scientist under Professor Gary Halliday and A/Prof. Guy Lyon in the Dept. of Dermatology, RPAH, The University of Sydney.
He have published â79 peer-reviewedâ (34 journal articles and 45 conference proceedings) articles in high impact leading journals. Currently, his total H index is 12 and total citation 368 with a total impact factor 68.60. Among all publications, he have six ERA âA* Rankedâ publications and ten ERA âA Rankedâ published articles (high ranked journals according to ISI Journal Citation Reports). He have presented more than 45 national and international conferences and also invited as a symposium speaker and Panel discussion member in several countries (e.g. Japan, Canada and Australia etc).
He achieved several competitive Government âresearch grantsâ in Australia (ADRF student grant, 2014-2015) and Japan (Centre of Excellence Research Grant 2007-2008, JSPS 2008-10, UNESCO Japan Funds-in-Trust, 2007).
For a complete list of his external and internal grants please visit the Professional section.
He has achieved several âcompetitive awardsâ in the field of Dentistry one of them was âGeriatric Research post doctoral Award 2010â in IADR Barcelona, Spain and âGeriatric research pre-doctoral Awardâ in IADR, Brisbane, Australia in March 2006.
Since 2002, he have been successfully âcollaborating internationallyâ in several research projects with several countries (e.g. Australia, Japan and Bangladesh etc) and published in high ERA ranked journals from these collaboration research works.
For a complete list of his Academic distinctions please visit âAwards and collaborationâ section.
He have been supervising 3 undergraduate students in several ethics approved ADRF funded research projects at CSU. He have been working as a Co-supervisor for 2 Honors students at CSU. He had been âPhD Co-supervisorâ for several students at the Faulty of Dentistry, Okayama University, Japan.
Currently, he is a member of CSU Human Research Ethics Committee (HREC), Member of CSU learning and teaching committee and also member of CSU Research Committee.
He is currently an active member of various national and international societies (e.g. ANZACA, AIAS, IADR, JADR, MEPSA, JCA etc). He have been regularly reviewing high quality journal and conference papers.
Realization of chemotherapy treatments, radiation therapy indication. Execution of Clinical Research of different gastric tumors, endocrine, Gist, esophageal, pancreas, breast with the use of drugs in clinical research allowed. Teaching lectures to the community and different thematic Television on cancer and the environment. Publications in various medical journals of Argentina and neighboring countries. Clinical Oral Oncology, Oral Diagnostics, Premalignancy Diseases, Mammography.
Daniela Capdepon, graduate of the University F. Medical BarcelĂł in 2001 with honors and highest academic average. Make residency in Internal Medicine at the Municipal hospital and COBA oriented Graduate Clinical Oncology from 2002 to 2004. Then I began to study the specialty of Clinical Oncology at the University of Salvador, trained in gastric tumors in Udaondo Hospital, Hospital Marie Curie Cancer Center and Henry Moore at where we learned to prepare and deliver chemotherapies and concurrences to form the pallium Center for palliative treatment of pain. Graduated in the specialty of clinical oncologist and palliative medicine subspecialty in Pain in 2006 of Salvador University, Buenos Aires. Oncologist at Work as outpatient and outpatient chemotherapy treatments made in Municipal Hospital and Italian Society of Zarate and Campana. Fellow in Fundaleu as subinvestigadora in Oncohematology and where do my training in liquid tumors, LLC, ALL MM, NHL LH. During 2006-2007. In 2008 I built my own Cancer Center, of which I am the owner and medical director, is Campana Cancer Center, where cancer care is done in outpatient chemotherapy treatments and pain and palliative treatments. Together with a specialized team that works with me. We also conduct Cancer Center, clinical research protocols in various tumors. Starting a new labor stage in the province of Entre Rios as oncologist responsible for the service in Peru Galarza General Hospital. And St. Joseph Medical Center Villa Paranacito, where consultations and cancer treatments are performed.
Oncology; Chemotherapy and Biological Therapy; Nuclear Medicine; Internal Medicine
March 2000 - February 2001: Internship (Pre Registration)
Assiut University Teaching Hospitals (the tertiary hospital of the Upper Egypt, 2000 beds), and Ministry of public Health Hospitals.
Rotating on Internal Medicine, Surgery, Gynecology, Emergency and anesthesia, pediatrics and Rheumatology and rehabilitation.
March 2001- March 2005: Resident and Senior Resident:
âOncology department, Assiut University Hospital â
A) Morning duties:-Attending 2 outpatient clinics per week for diagnosis and further management.. rotating on all clinical divisions covering all cancers including solid tumours and hematological malignancies units.
- Chemotherapy administration including intrathecal protocols.
-Preparation of the daily clinical round for all admitted patients.
-Preparation of the weekly clinical conference and presenting the cases, clinical , radiological, and discussing them with professors.
B) 24 hours inhouse coverage: (Having a one of three roaster)
- care of all the inpatients in the department 24hours.
-Dealing with oncologic emergency and first aid measures.
April 2005 â Feb. 2007: oncology Specialist (assistant consultant ):
ministry of health in Assiut Al Eman Hospital since 2006 And Training part for the MD Study in Clinical Oncology in Cairo University Oncology center.
February 2007 âMarch 2010: oncology Specialist (Assistant Consultant) IN Saudi German Hospitals Group in Jeddah (JCI accredited Hospital):
- Chemotherapy, medical treatment, biological therapy, Immunotherapy and palliative care.
-Attending Inpatient and out patients clinic.
April 2010 âJanuary 2011: Mandatory advanced research and preparatory clinical rotation for the final exam (MD) in clinical oncology, Cairo University.
September and October 2010: clinical attachment United Kingdom ,Edinburgh Western General Hospital Oncology center.
February 2011- till Now: Clinical oncologist in King Abdullah Medical City (KAMC) Oncology center Jeddah, medical oncology Dept since 2012.
2014: Lecturer of Clinical Oncology : Aswan University.
1st to 16th July 2014: Clinical attachment at Velindre Cancer Centre, UK
September 2014: Announced as a winner of ESMO Fellowship in PC palliative care.
Head and Neck; Colorectal cancer and GIT Malignancies; Gynecological Malignancies; Brachytherapy
Associate Professor Radiation Oncology, National Cancer Institute (NCI), Cairo University. Department of Radiation Oncology and Nuclear Medicine National Cancer Institute (NCI), Cairo University Kasr El Aini Street, Fom El-Khalig Square Cairo â Egypt. Postal code: 11976
Nanoscale-based targeted delivery of drugs and/or siRNA in order to enhance the efficiency of treatment and imaging; Nanoparticle formulation; characterization and testing; preclinical in vitro and in vivo evaluation of anticancer therapeutics; lung diseases; personalized medicine; intracellular fate and molecular mechanisms of action of drugs; pharmacokinetics and pharmacodynamics;study and development of polymers to deliver drugs and/or siRNA for the treatment of cancer; Targeted inhalation delivery of drugs and siRNA using bio-engineered polymeric nanoparticles for the treatment of lung cancer
Nishant S. Gandhi Ph.D. is a visiting research scholar in the department of Pharmaceutics and drug delivery at the University of Mississippi, School of Pharmacy. He obtained his Ph.D. in Pharmaceutical Sciences from the Daniel K Inouye College of Pharmacy at University of Hawaii at Hilo. He has also completed his B.Pharm and M.Pharm (Pharmaceutics) from University of Pune in India. He has further worked as a chemist in Aristo Pharmaceuticals in Bhopal, India.He is a scientific professional with over eight years of academic and industry experience in oncology, and neurological disorders. He has a strong track record of building high-profile collaborations with professors from other universities. He is currently working on developing novel nanotechnology based drug delivery systems for the treatment of lung cancer. He has successfully published 4 research articles, 3 review articles and 3 book chapters. He is also currently serving as a reviewer for 5 reputed journals. He is a member of the American medical writerâs associationand has served as co-chair and vice chair of the University of Hawaii Student chapter of the American Association of Pharmaceutical Scientists (AAPS).
Avalon University School of Medicine Netherlands View Profile
Development of biomarker strategies in Hemato-Oncology; Musculoskeletal and Oncology Therapeutics and Diagnostics (Theranostics)
Sunil Aggarwal has fourteen years of medical review/advisor, medical monitor, protocol and strategy development with EMR expertise. Radiologist with lead role in oncology and musculoskeletal, and a physician with medical affairs expertise on biomarker and diagnostic and therapeutic project development, in clinical practice, ambulatory care, clinical research and drug/medical device development. Board Certified Radiologist, an MD with MBA and Master Black belt in Lean Six Sigma, Dr.Aggarwal is presently working as a Professor in Avalon University School of University, Curacao. Proficient with the entire spectrum of biomarker development and medical affairs/ medical monitoring with drug safety reports for Phase I to Phase III clinical trials. Experienced in interface with KOLs and other scientific and research personnel as per the requirements.
Oncoanesthesia; Transplant Anesthesia; Pain Management; Critical care; Advanced Trauma Life Support
Dr. Uma Hariharan is presently working as an Assistant Professor in Anesthesia and Intensive Care at Dr Ram Manohar Lohia Hospital and done her Post Graduate from Institute of Medical Education and Research, Central Health Services, Teaching Cadre, New Delhi (Central Health Services), Govt. of India. Previously she worked in Anesthesia and Intensive Care at Bhagwan Mahavir Hospital, Delhi Government Health Services, New Delhi.
Near-Total Laryngectomy; Orthotopic Neobladder; DeviceDevelopment and Research; Breast Cancer Stem Cell Research; Surgical Anatomy
Near-Total Laryngectomy: âPHYSIOLOGICAL CHANGES IN THE SHUNT CAN BE MODIFIED BY SURGICAL TECHNIQUESâ-Working closely with Phd research students and voice modulation therapists to improve quality of phonation in NTL patient groups. Data being generated to validate normal shunt pressures and ENG and ENMG in such patients. These data will be used to improve OR modify the surgical techniques presently used to construct the shunt.Actively involved in developing a cheaper Trachea-Esophageal Stent of INDIAN MAKE to suit Indian subcontinent patients.
Orthotopic Neobladder:Focusing mainly on four areas
a. Improve continence, potency in such patients by refining the technique of nerve identification and preservation.
b. Treatment and prevention of metabolic acidosis:
Leading a team of oncologists and urologists from various countries in validating a local instillationcompound (âpatented moleculeâ).
c. Working with self-help groups, counselors and psychologists âwork on motivational aspects of patientâs acceptance towards Neobladder.
d. Develop transurethral âSTAPLED ANASTOMOSISâ of urethral stump and the Neobladder.(successfully done the same in animal models)âreduce op time and leaks and improves continence
DeviceDevelopment and Research
Working with R&D staff of a reputed MNC to refine and develop a modified shear which would accommodate the needs of the hepatic surgeons---ergonomically superior, quick large bite, lessen lateral burns, and reduce OT hours of resections and transplantations.
Breast Cancer Stem Cell Research
Involved at various stages of developing âBREAST CANCER STEM CELLâ and
anti-breast cancer stem cell antibody.
Surgical Anatomy: Involved in validating extra peritoneal approach for hysterectomy and COMPARATIVE STUDY OF PELVIS IN animal models. This is mainly to develop surgical techniques to avoid nerve injuries during pelvic surgeries like Low Anterior resections, Radical hysterectomy and cystectomy. ANAL SPHINCTER PHYSIOLOGY:PROVIDE DATA TO DEVELOP AN ARTIFICIAL IMPLANTABLE ANAL SPHINCTER âNEAR FUTURE REALITY.
Clinical Oncology; Nuclear Medicine
MB.BCh (Bachelor of Medicine and Surgery) in September 1993, faculty of medicine, Assuit University, Egypt (WHO listed). (6 years of full time medical study in English, including basic and clinical medical study). Master degree in radiotherapy, Sohag Faculty of Medicine, South Valley University, Egypt, 1999. MD in radiotherapy, Faculty of Medicine, Sohag University, Sohag, Egypt, 2007.
National Cancer Institute, Cairo University Egypt View Profile
2003: Operating the Densitometry machine - Bone Densitometry Unit in Moustafa Mahmoudâs Hospital, Cairo, Egypt.
- 2003-2004: Observer - General Medicine Rounds in Moustafa Mahmoudâs Hospital, Cairo, Egypt.
- 2005-2006: House Officer - Kasr El Ainy Hospital, Cairo University, Egypt
Rotations included Emergency Department, Obstetrics and Gynecology, Genera Surgery, General medicine, Pediatrics, Radiodiagnosis and ICU.
- 2005-2006: Resident - El Salam Scan Center, Cairo, Egypt - Radiodiagnosis and Interventional Radiology Center.
- 2006-2009: Medical Oncology Resident - National Cancer Institute, Cairo University, Egypt.
- 2009: 3 months Observer - Allogeneic BMT Program, Princess Margaret Hospital, Toronto, Canada.
- 2009-2015: Assistant Lecturer - National Cancer Institute, Cairo University, Egypt.
- 2010: Clinical Fellow - Multiple Myeloma and Autologous Stem Cell Transplant Group, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
- 2011-2014: Oncology Specialist â As Salam international hospital Medical Oncology specialist, inpatient and outpatient units.
- 2014: Consultant of Medical Oncology, Air Force Specialized Hospital, Egypt.
- 2013-2015: Coordinator of the ESMO exam, Cairo session, National Cancer Institute, Egypt.
- 2015 â till now: Lecturer of Medical Oncology, National Cancer Institute, Egypt.
Rasha Haggag is an associate professor at the Medical Oncology Department, Zagazig University, Egypt. Following her M.B.B.Ch in 1998 and M.Sc. in General Medicine in 2004 from Zagazig University, Haggag pursued her MD degree in Medical Oncology at NCI, Cairo University in 2010. Thereafter, Haggag joined the Medical Oncology Department at NCI and became an Assistant Professor in 2015 till now. Haggag is a member of various professional organizations including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), European Arab School of Oncology (EASO), Breast gynecological cancer group (BCGC) and Egyptian hematology oncology group (EHOG). Haggag serves as an Editor in Advances in Oncology Research and Treatments journal and Journal of Unexplored Cancer Data.
Health Science Communications; Healthcare Innovation; Health Policy; Health Disparities; Oncology; Pharmacology; Translational Science; Implementation Science; Intellectual Property
Bridgette F. Peake, MS, is a Pharmacology PhD candidate working at Emory Universityâs Winship Cancer Institute with Dr. Lily Yang. Her current research investigates mechanisms of resistance and refined methods of targeted therapy in metastatic strains of breast cancer. She is passionate about using effective communication to bridge the gap between the complexities of scientific discovery and public. While pursing her Masterâs degree at Western Illinois University she had the opportunity to work in the field with local farmers. This experience taught her how to translate benchtop discoveries into pragmatic, yet innovative solutions for crop production. Prior to beginning her PhD studies,Bridgette worked as a research specialist at Emory University. She executed microarray analyses to enhance clinical based testing methods in prostate and uterine cancer. She further mediated collaborative efforts between the Emory Clinical Translational Research Laboratory, young investigators, pharmaceutical companies and industry affiliates to establish a tissue bank for multivariable analyses. From this work she developed an interest in scientific communications, with an emphasis on mediating collaborative efforts between all fields of science. She is currently a trainee in the competitive NIH BEST program, where she has the opportunity to explore how alternative careers in science significantly contribute to discovery and innovation in academia.
Resistance to therapy severely limits the effectiveness of chemotherapy drugs in treating cancer; For Advanced Cancer, the progression of tumors to the state of chemoresistance; the paucity of knowledge about the mechanism of chemoresistance and lack of therapeutic molecule/s are major stumbling blocks in the management and treatment of disease in cancer patients; Primary or acquired drug resistance remains a fundamental cause of therapeutic failure in cancer therapy;different cells; gene; proteins contribute to initiation, progression, and Chemoresistance of cancer; contribute to initiation, progression, and Chemoresistance of cancer not only facilitates rational treatment strategies to overcome existing limitations in therapeutic efficacy but will enhance biomarker discovery and the development of companion diagnostics
Dr. Hifzur R Siddique is Assistant Professor at Aligarh Muslim University in the Department of Zoology, Section of Genetics where he serves as the Program Director of Molecular Cancer Genetics and Translational Research. He actively serves on numerous boards, committees, scientific societies/associations, and charitable organizations, as well as, presents educational talks to students and the public. He regularly published popular articles on different subjects. Dr. Siddique obtained BS from Assam University, India, and MS from Aligarh Muslim University, India. Finally, he earned his Ph.D. degree from the Indian Institute of Toxicology Research. Dr. Siddique has numbers of scientific articles published in highly reputed high impact international journals. He also published 35 abstracts published in conference proceedings and 14-awards/honors to his credit. He obtained research training at internationally acclaimed institutes such as Indian Institute of Toxicology Research, University of Louisiana, University of Wisconsin, University of Minnesota, University of Southern California and Moffitt Cancer Center, USA, under the supervision of highly acclaimed and internationally renowned scientists who are well-known in their research areas.
Radiation Oncology Management of: Head and Neck Cancer; Upper and Lower GI Malignancy; Liver SBRT; GU malignancy; Breast Cancer
Completed undergraduate and clinical oncology training at Mansoura University, Egypt
Had Master degree in clinical oncology in 2011, and enrolled in PhD at Mnasoura University since 2012 with focus in accelerated fractionation radiotherapy in head and neck cancer. University staff of clinical oncology in Mansoura University since 2011, and joined Princess Margaret Cancer Centre radiation oncology fellowship program in Toronto, Canada since 2013.
Biomedical research scientist with eight yearsâ experience in investigating immune cell activation, development, and role of coagulation proteases in inflammation and immunity. Led a large collaboration for vitro and in vivo preclinical testing and pharmacology of bio therapeutics for sepsis, stroke, and GVHD. Isolated various primary cells and stem cells to serve a model for biomarker research, diagnostic tools, and cell therapy for sepsis and inflammation. A well specialized in immunology, hematology, biochemistry, oncology, and cell signaling. Exploratory mindset, creative, proactive, innovative researcher and team player to find solutions for difficult challenges. Organize and prioritize multiple projects (National & international) / initiatives in an academic-entrepreneurial environment with acute focus on timelines, goals, and success metrics. Looking to utilize my expertise in immunotherapy.
Designing, developing, and executing a complex scientific research in leukemia, T cell proliferation, cell signaling, molecular and cellular immunology, metastasis, analytical biochemistry and pharmacology for enzyme based drug discovery in order to advance preclinical development.
Actively involved in T cell and NK cell development & activation, lipid and protein kinase mediated signaling, RTK and GPCR signaling, cell engineering to develop a drug in cancer, sepsis, inflammation, GVHD, and neuronal stroke.
Working on cellular immunology and immuno phenotyping of immune cells in different compartment of lymphoid organ and leading the cell biology group to study endothelial cells, lungs cells, and Mesenchymal Stem Cells (MSCs)âs functions in response to GPCR biased signaling.
Oncology; Advacnced 3D imaging; Cancer Radiology; Imaging Clinical trial and the Detection of Novel Imaging and Biological Biomarker
Rahmanuddin is a medical doctor with extensive knowledge & training in Oncology, advanced imaging for CT/ MR and US modality. Rahmanuddin is affiliated with the Nationâs most prestigious research and cancer institute City of Hope.
Rahmanuddin performs Body, Musculoskeletal, Neuro and Breast advanced imaging 3D cases. His major interest to acquire extensive knowledge for the following areas,
â˘Pharmaceutical Imaging Clinical Trials for CT/ MR and US
â˘Liver Oncology volumetric assessment for HCC patient including the surgical planning for Liver transplant and Hepato-billiary tumor surgeries
â˘3D Planning for RF liver tumor therapy
â˘Urologic tumor assessment including the tumor mapping with detailed delineation of renal anatomy including tumor volumetry
â˘3D assessment of Renal stones
â˘3D Quantitative prostate tumor assessment
â˘Angiography of renal and mesenteric arteries and peripheral runoff
â˘3D virtual assessment of Colon/ Colonography
â˘3D Lung assessment for Nodule, Screening and surgical planning
â˘Advanced Volumetric imaging for MSK trauma cases including the surgical planning for Spine and Orthopedic surgeries
â˘Cardiac and Coronary detailed analysis with Calcium scoring with stenosis measurement
â˘Cardio-Vascular surgical planning including stent placement planning
â˘3D Cardiac assessment for malformation
â˘3D advanced imaging for detailed Neurovascular exams for the assessment of Aneurysm & Stenosis measurement with curved reformatting
â˘3D Brain tumor mapping with pre-surgical planning
â˘3D Advanced tumor assessment for Breast MRI
Gehan Lotfy has completed herMD at the age of 35 years from Minia University andpediatric oncology board at 2015.She is the director of pediatric hematology and oncology unit.She had published more than 10 papers in reputed journals and hadshared in many international pediatric hematology and oncology congresses. She is an Egyptian pediatric board trainer since 2011.
Ph.D., Chemistry and Chemical Biology, Rutgers-The State University of New Jersey, NJ, USA January 2014; Thesis advisor: Dr. Ki-Bum Lee; Thesis: Multifunctional nanomaterials for advanced molecular imaging and cancer therapy; M.Sc., Chemistry, University of Delhi, Delhi, India July 2007; B.Sc. (Honors), Chemistry, University of Delhi, Delhi, India July 2005
Ashirwad Children & Cancer Precision Care Medical Center India View Profile
Targeted treatment in both Chemotherapy and Radiotherapy in oncology; Breast; Brain; Gynecology; Head and Neck Tumors
Shravan Kumar studied his MBBS, MD in oncology practices chemotherapy and radiotherapy. Extensively practicing targeted treatment in both chemotherapy and radiotherapy in oncology see complete spectrum of all types of oncology cases. Trained in well known academic institutions extensively under well known faces of oncology world. He has Handled all types of complicated cases easily. He has updated his knowledge on daily basis using all available online and offline resources. Attend extensively CMEs, CEs and conferences to meet and discuss with my superiors. He also worked for medical insurance as senior validator and super specialist.
Oncology Imaging; Cancer Imaging Abdominal; Pelvic Oncology Imaging
Amirali Khodayari Namin is an experienced Clinical Radiologist and Post-Doctoral Research Fellow in Medical Imaging with sound knowledge and experience of multimodality interventional/cross-sectional imaging. Able to design and implement research protocol while ensuring full compliance with ethics, guidelines and regulations. A compassionate advocate for patients and for the development of a safe health care system. Utilizes excellent communication skills to engage with patients, relatives and other health care professionals. Works collaboratively as part of a multidisciplinary team with a shared commitment to delivering high quality patient care.
He has a private practice specializing in endocrine (thyroid and parathyroid), head and neck oncologic surgery. He is expertise in minimally invasive thyroid and parathyroid surgery also expertise in oral, laryngeal and salivary gland surgery. He is a Member of a multidisciplinary team for craniofacial surgery affiliated with the University of Athens for thyroid and oral carcinogenesis research.